Preliminary Investigation of the Molecular Mechanism of Empagliflozin Suppressing Gastric Cancer Through Mammalian Target of Rapamycin

To predict the intervention targets of empagliflozin (EMPA), a specific inhibitor of sodium-glucose cotransporter 2 (SGLT2), in gastric adenocarcinoma through comprehensive network pharmacology, and to validate the effects and the molecular mechanisms of EMPA through cellular and molecular biology experiments.   Methods   Bioinformatics analysis of gastric adenocarcinoma was conducted to assess the correlation between gastric adenocarcinoma prognosis and SGLT2 expression. Network pharmacology was utilized to identify shared targets of EMPA and gastric adenocarcinoma. AGS cells, a human gastric adenocarcinoma cells line, were incubated with EMPA at different concentrations for 24 h and, then, cell proliferation was assessed using the CCK8 assay. After AGS cells were incubated with EMPA at the doses of 0, 3, and 6 mmol/L, real-time cell analysis (RTCA) and 5-ethynyl-2-deoxyuridine (EdU) incorporation were used to evaluate EMPA's inhibitory effects on the proliferation of the AGS cells. In addition, wound healing and Transwell assays were performed to assess the inhibitory effect of EMPA on the migration and invasion of the APC cells and Western blot analysis was conducted to examine the expression of mammalian target of rapamycin (mTOR) and phosphorylated mTOR (p-mTOR). BALB/c (nu/nu) nude mice were implanted with 5×106 AGS cells in the axilla. The mice were divided into three groups, a control group, a low-dose group, and a high-dose group, each consisting of 7 mice. After one week, the control group received daily intraperitoneal injections of normal saline, while the low-dose group and high-dose group received daily intraperitoneal injections of EMPA at the doses of 3 mg/kg and 5 mg/kg, respectively. The tumor volume was measured one week after the drug intervention started.   Results  Gastric adenocarcinoma patients with low expression of SGLT2 exhibited longer survival time and higher survival rate than those with high expression of SGLT2 did. A total of 104 EMPA-related potential targets and 2028 targets associated with gastric adenocarcinoma were identified. Among these, 45 targets associated with gastric adenocarcinoma overlapped with potential targets of EMPA. Further analysis revealed 10 relevant pathways and 4 core genes. The core genes were cyclin-dependent kinase 4 (CDK4), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), mTOR, and cyclin E1 (CCNE1). CCK-8 assay revealed that EMPA at concentrations ranging from 0.39 to 50 mmol/L effectively inhibited the proliferation of AGS cells. RTCA results indicated a downward shift in the cell growth curve. In comparison to the findings for the control group, EdU assay demonstrated that EMPA at the concentrations of 3 mmol/L and 6 mmol/L significantly inhibited AGS cell proliferation (P<0.05). Results from wound healing and Transwell assays indicated a decrease in the levels of cell migration and invasion (P<0.05) and, notably, there was a significant difference between the high and low-dose EMPA groups (P<0.05). Western blot showed no statistically significant difference in the expression of total mTOR protein between the groups. However, the expression of p-mTOR in the 3 mmol/L and 6 mmol/L EMPA groups decreased compared to that of the control group (P<0.05), with the 6 mmol/L EMPA group exhibiting a more pronounced reduction (P<0.05). Nude mice xenograft tumor experiment demonstrated that, compared to that of the control group, the tumor volumes in the EMPA-treatment groups were significantly reduced (P<0.05), with the high-dose group showing a more pronounced reduction (P<0.05).  Conclusion  EMPA inhibits the abnormal proliferation and migration of gastric adenocarcinoma cells, potentially through the modulation of mTOR protein activation. This study provides new potential medication and intervention targets for gastric adenocarcinoma treatment.

 

Keywords: Sodium-glucose cotransporter 2,  Empagliflozin,  Gastric adenocarcinoma,  Integrated network pharmacology,  mTOR

 

CORREA P. Gastric cancer. Gastroenterol Clin North Am，2013，42(2): 211–217. doi: 10.1016/j.gtc.2013.01.002.

BRAY F， FERLAY J， SOERJOMATARAM I， et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin，2018，68(6): 394–424. doi: 10.3322/caac.21492.

LORENZEN S， STAHLl M， HOFHEINZ R D， et al. Influence of taxanes on treatment sequence in gastric cancer. Oncol Res Treat，2020，43(1/2): 42–47. doi: 10.1159/000503428.

NI L， YUAN C， CHEN G， et al. SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol，2020，19(1): 98. doi: 10.1186/s12933-020-01071-y.

VALLON V， THOMSON S C. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia，2017，60(2): 215–225. doi: 10.1007/s00125-016-4157-3.

XIE Z， WANG F， LIN L， et al. An SGLT2 inhibitor modulates SHH expression by activating AMPK to inhibit the migration and induce the apoptosis of cervical carcinoma cells. Cancer Lett，2020，495: 200–210. doi: 10.1016/j.canlet.2020.09.005.

JOJIMA T， WAKAMASTU S， KASE M， et al. The SGLT2 inhibitor canagliflozin prevents carcinogenesis in a mouse model of diabetes and non-alcoholic steatohepatitis-related hepatocarcinogenesis: association with SGLT2 expression in hepatocellular carcinoma. Int J Mol Sci，2019， 20(20): 5237. doi: 10.3390/ijms20205237.

QUAGLIARIELLO V， De LAURENTIIS M， REA D， et al. The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol，2021，20(1): 150. doi: 10.1186/s12933-021-01346-y.

MORGAN E， ARNOLD M， CAMARGO M C， et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: a population-based modelling study. EClinicalMedicine，2022，47: 101404. doi: 10.1016/j.eclinm.2022.101404.

SCAFOGLIO C， HIRAYAMA B A， KEPE V， et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci U S A，2015，112(30): E4111–9. doi: 10.1073/pnas.1511698112.

GRONDA E， JESSUP M， IACOVIELLO M， et al. Glucose Metabolism in the kidney: neurohormonal activation and heart failure development. J Am Heart Assoc，2020，9(23): e018889. doi: 10.1161/jaha.120.018889.

ZHANG X， ZHANG X， LIU X， et al. MicroRNA-296, a suppressor non-coding RNA, downregulates SGLT2 expression in lung cancer. Int J Oncol，2019，54(1): 199–208. doi: 10.3892/ijo.2018.4599.

KOMATSU S， NOMIYAMA T， NUMATA T， et al. SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation. Endocr J，2020， 67(1): 99–106. doi: 10.1507/endocrj.EJ19-0428.

DICEMBRINI I， NREU B， MANNUCCI E， et al. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: a meta-analysis of randomized controlled trials. Diabetes Obes Metab，2019，21(8): 1871–1877. doi: 10.1016/j.biopha.2020.110821.

HSIA D S， GROVE O， CEFALU W T. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes，2017，24(1): 73–79. doi: 10.1097/med. 0000000000000311.

TSA K F， CHEN Y L， CHIOU T T， et al. Emergence of SGLT2 inhibitors as powerful antioxidants in human diseases. Antioxidants (Basel)，2021，10(8): 1166. doi: 10.3390/antiox10081166.

WRIGHT E M. SGLT2 and cancer. Pflugers Arch，2020，472(9): 1407–1414. doi: 10.1007/s00424-020-02448-4.

OBARA K， SHIRAKAMI Y， MARUTA A， et al. Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice. Oncotarget，2017，8(35): 58353–58363. doi: 10.18632/oncotarget. 16874.

DONG X， HU X， CHEN J， et al. BRD4 regulates cellular senescence in gastric cancer cells via E2F/miR-106b/p21 axis. Cell Death Dis，2018，9(2): 203. doi: 10.1038/s41419-017-0181-6.

ZHANG W， LI Y， LYU J， et al. An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma. Cancer Sci，2022，113(3): 891–903. doi: 10.1111/cas.15254.

YANG J， NIE J， MA X， et al. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer，2019，18(1): 26. doi: 10.1186/s12943-019-0954-x.

HERRERA-ABREU M T， PALAFOX M， ASGHAR U， et al. Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res，2016，76(8): 2301–2313. doi: 10.1158/0008-5472.Can-15-0728.

PACCHIANA R， MULLAPPILLY N， PINTO A， et al. 3-bromo-isoxazoline derivatives inhibit GAPDH enzyme in PDAC cells triggering autophagy and apoptotic cell death. Cancers (Basel)，2022，14(13): 3153. doi: 10.3390/cancers14133153.

LIBERTI M V， LOCASALE J W. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci，2016，41(3): 211–218. doi: 10.1016/j. tibs.2015.12.001.

LANG S A， GAUMANN A， KOEHL G E， et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer，2007，120(8): 1803–1810. doi: 10.1002/ijc.22442.